Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4252033 | 1.00 | TGFBR1 (0.41) | TGFBR1TGFBR2 | |
| SCHEMBL13891591 | 0.78 | TGFBR1 (0.35) | TGFBR1TGFBR2 | |
| SCHEMBL12998314 | 0.78 | POLB (0.43) | TGFBR1TGFBR2 | |
| SCHEMBL3770639 | 0.78 | MAP3K14 (0.43) | TGFBR1TGFBR2 | |
| SCHEMBL4252029 | 0.77 | TGFBR1 (0.39) | TGFBR1 | |
| SCHEMBL4251225 | 0.70 | TGFBR1 (0.62) | TGFBR1 | |
| SCHEMBL4256827 | 0.70 | TGFBR1 (0.47) | TGFBR1 | |
| SCHEMBL13745783 | 0.70 | TGFBR1 (0.40) | TGFBR1 | |
| SCHEMBL4250098 | 0.67 | TGFBR1 (0.55) | TGFBR1 | |
| SCHEMBL4253849 | 0.65 | CHEK1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-27 | — | — | US | disclosed |
| WO-2008014219-A2 | THIOZOLIDINEDIONE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215818-A1 | THIOZOLIDINEDIONE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PI4KA, PIP4K2A | TGFBR1 444/4885TGFBR2 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.